



Memorial Sloan Kettering Cancer Center

# International Precision Oncology Tumor Board Targeting the KRAS Pathway: Expert Perspectives

Wednesday, 26 April, 2023  
6pm IST | 8:30am ET

[REGISTER HERE](#)

Interpreting results from next-generation genomic sequencing of cancer, and identifying the right drug for the right patient, is a challenge for many cancer specialists today. Join leading global experts for a new educational series where we'll take a deep dive into each of the major cancer signaling pathways and discuss the nuances of precision therapies. In this quarterly series, we will begin with *KRAS* and subsequently focus on *BRAF*, *EGFR*, *HER2*, *BRCA* and *HRD*, *RET/ALK*, *FGFR*, and emerging pathways.

## Course Directors



### Dr. Sewanti Limaye

Director of Medical &  
Precision Oncology  
Sir HN Reliance Foundation Hospital,  
Mumbai



### Dr. Mrinal Gounder

Medical Oncology,  
Early-Phase Clinical Trials  
MSK, New York

## Expert Panelists



### Dr. Ullas Batra

Chief of Thoracic Medical Oncology  
Rajiv Gandhi Cancer Institute, New Delhi



### Dr. Gregory Riely

Thoracic Medical Oncology  
MSK, New York



### Dr. Vijay Agarwal

Medical Oncology Lead  
Apollo Hospitals, Bangalore



### Dr. T. Raja,

Director of Medical Oncology  
Apollo Cancer Centre, Chennai



### Dr. Yonina Murciano-Goroff

Medical Oncology, Early Phase Clinical  
Trials, MSK, New York



### Dr. Rona D. Yaeger

Gastrointestinal Medical Oncology  
MSK, New York



### Dr. Debyani Chakravarty

Clinical Cancer Genomics  
MSK, New York



### Dr. Bhuvan Chugh

Senior Consultant Medical Oncology  
Max Hospital, New Delhi



Memorial Sloan Kettering  
Cancer Center

iClinic+

Powered by The Virtual Hospital

# KRAS Pathway Experts

**Gregory Riely, MD, PhD** is an Attending Medical Oncologist specializing in lung cancer. He led the clinical trial of adagrasib, KRAS inhibitor in lung cancer that led to the US FDA approval and subsequently described the mechanisms of acquired resistance to KRAS inhibitors – both reported in the New England Journal of Medicine.

**Rona Yaeger, MD** is an Attending Medical Oncologist specializing in GI and colorectal cancer. She led the clinical trials of KRAS inhibitors sotorasib and adagrasib with or without cetuximab in pancreatic and colorectal cancers, respectively – both reported in the New England Journal of Medicine. She described mechanisms of resistance to KRAS and EGFR inhibitors – Cancer Discovery.

**Yonina Murciano-Goroff, MD, MSc, DPhil** is an Attending Medical Oncologist specializing in early phase clinical trials across cancers. She is working on developing the next-generation of KRAS inhibitor therapies for non *G12C* KRAS mutations and overcoming resistant mechanisms – published in Nature, Nature Reviews Clinical Oncology, and Cancer Discovery.

**Debyani Chakravarty, PhD**, is a molecular geneticist specializing in Cancer Genomics and the accurate clinical interpretation of patient tumor molecular profiles. She led the creation of OncoKB™, a FDA-recognized precision oncology knowledge base providing levels of evidence for NGS results ([www.oncoKB.org](http://www.oncoKB.org)).

## Scientific Committee

Alex Drilon, MSK, NY  
Amit Rauthan, Manipal, Bangalore  
David Solit, MSK, NY  
Deborah Schrag, MSK NY  
Jyoti Bajpai, TMH, Mumbai  
Kumar Prabhash, TMH, Mumbai

Luis Diaz, MSK, NY  
Marc Ladanyi, MSK, NY  
Marcel Van Den Brink, MSK, NY  
Michael Berger, MSK, NY  
Nitesh Rohatgi, Fortis, New Delhi  
R Vijayalakshmi, CI – Adayar, Chennai

Ross Levine, MSK, NY  
S. Sushil, CMC, Vellore  
Sameer Rastogi, AIIMS, New Delhi  
Sewanti Limaye, Reliance, Mumbai  
T. Raja, Apollo, Chennai  
Ullas Batra, RGCI, New Delhi  
Vicky Makker, MSK, NY

## Organizing Physicians



**Sir Dr. Murray Brennan**  
MSK New York



**Dr. Mrinal Gounder**  
MSK New York



**Dr. Sewanti Limaye**  
Sir HN Reliance Foundation Hospital, Mumbai



**Dr. Varadarajan Kumar**  
MSK India, Chennai

## Contact Information

**MSK India**

5, Subba Rao Avenue, 1st St, Chennai, Tamil Nadu 600006, India

Email: [mskccindia@icliniq.com](mailto:mskccindia@icliniq.com) Phone: +91-82700-70000

<https://in.mskcc.org/india>



Memorial Sloan Kettering  
Cancer Center

iCliniq  
Powered by The Virtual Hospital